ReviewWorld journal of pediatrics : WJP2021
Standards of care for Kasabach-Merritt phenomenon in China.
Review in World journal of pediatrics : WJP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Antibody levels and immune memory in children with kaposiform hemangioendothelioma treated with sirolimus after catch up vaccination.Human vaccines & immunotherapeutics · 2026Article
- Kaposiform hemangioendothelioma: Diagnosis and treatment.Pediatric investigation · 2026Review
- Immunological and clinical characteristics of severe thrombocytopenia in neonates with Kasabach-Merritt phenomenon.Frontiers in immunology · 2026Article
- Case Report: Surgical management of giant hepatic cavernous haemangioma with Kasabach-Merritt syndrome in an adult.Frontiers in medicine · 2026Article
- Corticosteroid-to-sirolimus sequential therapy: a case series of infantile kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon.Translational pediatrics · 2025Article
- Retroperitoneal infantile hemangioma: a case report and literature review.Discover oncology · 2024Article
- Treatment experience for different risk groups of Kaposiform hemangioendothelioma.Frontiers in oncology · 2024Article
- Platelet functional abnormalities in pediatric patients with kaposiform hemangioendothelioma/Kasabach-Merritt phenomenon.Blood advances · 2023Article
- Impact of age and tumor size on the development of the Kasabach-Merritt phenomenon in patients with kaposiform hemangioendothelioma: a retrospective cohort study.Precision clinical medicine · 2023Article
- Case Report: Kaposiform hemangioendothelioma with PIK3CA mutation successfully treated with sirolimus.Frontiers in oncology · 2023Article
- Cocktail therapy with prednisolone, vincristine and sirolimus for Kasabach‑Merritt phenomenon in 10 infants.Experimental and therapeutic medicine · 2022Article
- Case report: Experience of a rare case of rebound of the Kasabach-Merritt phenomenon during sirolimus treatment in kaposiform hemangioendothelioma.Frontiers in pediatrics · 2022Article
- Kasabach-Merritt Phenomenon: Diagnosis, Management, and Outcome on Two Cases in a Sub-Saharan Country (Senegal).Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kasabach-Merritt phenomenon (KMP) is a rare disease that is characterized by severe thrombocytopenia and consumptive coagulation dysfunction caused by kaposiform hemangioendothelioma or tufted hemangioma. This condition primarily occurs in infants and young children, usually with acute onset and rapid progression. This review article introduced standardized recommendations for the pathogenesis, clinical manifestation, diagnostic methods and treatment process of KMP in China, which can be used as a reference for clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.